Abstract Details

Title Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Preg study conducted in Finland and Sweden

Topic Multiple Sclerosis

Presentation(s) S49 - MS Epidemiology and Risk Stratification (1:44 PM-1:55 PM)

Poster/Presentation
Number 005

Objective To assess the prevalence of pregnancy and infant outcomes in interferon-beta (IFNβ) exposed pregnant women with multiple sclerosis (MS) from European IFNβ pregnancy registry and Nordic health registers.

Background Women with MS are often diagnosed and treated at childbearing age. Earlier studies suggest that MS and IFNβ exposure do not adversely affect pregnancy outcomes; however, data has been limited. To address this, a European IFNβ pregnancy registry was established and a population-based cohort study (MS Preg study) was conducted with data from Nordic health registers in Finland and Sweden.

Design/Methods In the European registry, pregnant women identified themselves to the Marketing Authorization Holders (Bayer, Biogen, Merck, Novartis) or healthcare professionals as exposed to IFNβ shortly before conception, or anytime during pregnancy. In Finland and Sweden, women treated with IFNβ within three months prior to or during pregnancy were considered as exposed. Collected pregnancy outcomes included congenital anomalies, spontaneous abortions, elective terminations, ectopic pregnancies, stillbirths and live births. The prevalence of pregnancy outcomes in IFNβ-exposed women in the European registry and the Nordic data are presented, alongside a cohort of women from the Nordic dataset with MS but unexposed to MS treatment.

Results A total of 948 and 875 IFNβ-exposed pregnancies with known pregnancy outcomes were collected from the European registry (Eur) and the Nordic registers, respectively. Similar prevalences of spontaneous abortions (10.7% Eur; 7.9% Nordic vs. 11.1%), live births with congenital anomalies (1.8% Eur; 1.8% Nordic vs. 3.3%) and ectopic pregnancies (0.4% Eur; 1.5% Nordic vs. 2.9%) were found in the IFNβ-exposed pregnancies versus the non-exposed cohort; in line with rates from the general population. Additional analyses on pregnancy outcomes will be presented.

Conclusions The European IFNβ pregnancy registry showed no evidence that IFNβ exposure before conception and/or during pregnancy adversely affected pregnancy or infant outcomes; consistent with data collected from the Nordic registers.

Authors/Disclosures
Kerstin Hellwig (St. Josef Hospital Bochum) PRESENTER	Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mylan . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche . The institution of Kerstin Hellwig has received research support from Roche . The institution of Kerstin Hellwig has received research support from Merck . The institution of Kerstin Hellwig has received research support from Biogen. The institution of Kerstin Hellwig has received research support from Genzyme . The institution of Kerstin Hellwig has received research support from Novartis . The institution of Kerstin Hellwig has received research support from BMS .
Yvonne Geissbuhler (Novartis Pharma AG)	No disclosure on file
	No disclosure on file
	No disclosure on file
Alessandra Adamo	No disclosure on file
	No disclosure on file
Peter Huppke	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Mayra Mori	No disclosure on file

��ɫ��

��ɫ��